(CercleFinance.com) – Innate Pharma announces positive results from the phase II TELLOMAK study evaluating its lacutamab in mycosis fungoides, during the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Treatment with lacutamab showed clinically significant antitumor activity in heavily pretreated patients, independently of the level of KIR3DL2 expression, with a safety profile similar to that previously observed.
“These results are very promising and support the continued development of lacutamab in order to provide better treatments for patients with cutaneous T-cell lymphomas,” comments medical director Sonia Quaratino.